Related Experiment Video
Updated: Sep 25, 2025

07:42
Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients
Published on: December 16, 2022
3.1K
External Validation of the Passive Surveillance Stroke Severity Indicator
Raed A Joundi1, James A King2, Jillian Stang3
1Division of Neurology, Hamilton Health Sciences, McMaster University & Population Health Research Institute, Hamilton, ON, Canada.
Summary
The Passive Surveillance Stroke Severity (PaSSV) Indicator improves stroke severity estimation from administrative data. This validation confirms PaSSV
Area of Science:
- Neurology
- Public Health
- Health Informatics
Background:
- The Passive Surveillance Stroke Severity (PaSSV) Indicator was developed to estimate stroke severity using administrative data.
- External validation of the PaSSV Indicator was lacking.
Purpose of the Study:
- To externally validate the Passive Surveillance Stroke Severity (PaSSV) Indicator.
- To assess the impact of incorporating stroke severity on predictive models for acute stroke outcomes.
Main Methods:
- Linked administrative datasets for first-time acute stroke hospitalizations in Alberta, Canada (2007-2018).
- Utilized Cox proportional hazard models and logistic regression to evaluate the PaSSV Indicator's effect on case fatality and home time outcomes.
- Compared model performance with and without PaSSV, and with the National Institutes of Health Stroke Scale (NIHSS) in a clinical registry sample.
Main Results:
- The addition of PaSSV significantly improved model discrimination for 30-day case fatality (C-statistic increased from 0.72 to 0.80).
- PaSSV adjustment revealed that comprehensive stroke center admission was associated with lower 30-day case fatality (aHR changed from 1.03 to 0.72).
- Similar improvements in model discrimination were observed for 1-year case fatality and home time outcomes.
Conclusions:
- The PaSSV Indicator enhances model discrimination for acute stroke case fatality and home time outcomes.
- External validation in Canadian provinces supports the utility of PaSSV for baseline risk adjustment in acute stroke patients.

